to September 2018, and Vice President, EU Regulatory Sciences from 2012 to 2015 at Bristol Myers Squibb, a global biopharmaceutical company. Dr. Rupalla holds a M.Sc. in Pharmacy and a Ph.D.
in CNS Pharmacology from the Philipps-University Marburg, Germany, an M.B.A. from Jones International University and a Non-Executive Director Diploma (UK) (Pearson Level 7) from the Financial Times. Our Board and Nominating Committee believe
Dr. Rupallas experience working in senior leadership positions in life science companies and expertise and knowledge of regulatory matters qualifies her to serve as a member and chairperson of our Board.
Directors Continuing in Office Until the 2025 Annual General Meeting
Daniel J. OConnor, 58, has served as our director and as our President and Chief Executive
Officer since November 2022. Mr. OConnor has over 23 years of executive and leadership experience in all aspects of the biopharmaceutical industry, including as the chief executive officer of multiple public companies, including Seelos
Therapeutics, Inc. (Seelos), OncoSec Medical Incorporated (OncoSec), Advaxis, Inc. (Advaxis) and Larkspur Health Acquisition Corp. (Larkspur) (prior to its merger with ZyVersa Therapeutics, Inc.
(ZyVersa)), and as a C-level executive at ImClone Systems Incorporated (ImClone), BRACCO Diagnostics Inc. (BRACCO) and PharmaNet Development Group, Inc. (PharmaNet). Mr. OConnor is a
founding board member of Seelos, a clinical-stage biopharmaceutical company, serving on its board of directors since September 2018. Mr. OConnor founded Larkspur, a special purpose acquisition company, in March 2021 and served
as its Chief Executive Officer and Chairman of the board of directors until it merged with ZyVersa in December 2022, and, since then, has served as a member of the board of directors of ZyVersa, a public biopharmaceutical company.
Mr. OConnor served as Chief Executive Officer and as a member of the board of directors of OncoSec, a clinical-stage biotechnology company, from September 2017 to June 2021. From February 2016 to November 2021, Mr. OConnor
served as a member of the Board of Trustees of BioNJ, a non-profit organization representing research-based life sciences companies and stakeholders, and previously served as its Vice Chairman and Chairman of
its Nominating Committee for several years. Mr. OConnor also served as President, Chief Executive Officer, member of the board of directors and in other senior roles at Advaxis, a cancer immunotherapy company, from January 2013 to July 2017,
and previously served as Senior Vice President and General Counsel at BRACCO, a healthcare company, from 2008 to 2012, Senior Vice President, General Counsel and Secretary at ImClone, a biopharmaceutical company, from 2002 to 2008, and General
Counsel at PharmaNet, a clinical research company now known as Syneos Health, Inc., from 1998 to 2001. Mr. OConnor was also appointed to the New Jersey Biotechnology Task Force by its Governor. Mr. OConnor earned a J.D. from
the Dickinson School of Law of Pennsylvania State University and a B.A. in English from Boston University. He graduated from the United States Marine Corps Officer Candidate School in 1998 and was commissioned as an officer in the U.S. Marines,
attaining the rank of Captain while serving in Saudi Arabia during Operation Desert Shield. Our Board and Nominating Committee believes that Mr. OConnors extensive leadership experience in managing and directing biopharmaceutical
companies qualifies him to serve on our Board.
Paul Maier, 75, has served as our director since February 2022.
Mr. Maier currently serves as a board member of Small Pharma, Inc, a life science company, since November 2021, Eton Pharmaceuticals, Inc., a life science company, since September 2017, as a board member of Biological Dynamics, Inc., a private
diagnostics company, since November 2014 and as a board member of International Stem Cell Corporation, a life science company, since July 2007. Previously, Mr. Maier was the Chief Financial Officer at Sequenom, Inc., a genomic analysis company,
from 2009 to 2014. Mr. Maier also served as Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, from 1992 to 2007, and as independent financial consultant to certain life
sciences companies. Previously, Mr. Maier served on the board of directors of 4D Pharma PLC., a biotechnology company, from February 2021 to July 2022, Ritter Pharmaceuticals, Inc., a biotechnology company, from March 2015 until its merger with
Qualigen, Inc. in May 2020, Apricus Biosciences Inc., a pharmaceutical company, from May 2012 until its merger with Seelos in January 2019, and MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, from June
2014 to July 2018. Mr. Maier holds a B.S. in business logistics from the Pennsylvania State University and an M.B.A. from Harvard University. Our Board and Nominating Committee believes that Mr. Maiers
9